CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2017—Morphotek, a subsidiary of Eisai, has entered into a collaboration and license agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay for use on the Lumipulse system as a companion diagnostic to aid in the selection of ovarian cancer patients who may best respond to farletuzumab.
Read More »